Martin H Steinberg
Overview
Explore the profile of Martin H Steinberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
189
Citations
6526
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wonkam A, Esoh K, Levine R, Ngo Bitoungui V, Mnika K, Nimmagadda N, et al.
Nat Commun
. 2025 Mar;
16(1):2092.
PMID: 40025045
Known fetal haemoglobin (HbF)-modulating loci explain 10-24% variation of HbF level in Africans with Sickle Cell Disease (SCD), compared to 50% among Europeans. Here, we report fourteen candidate loci from...
2.
McManus M, Frangoul H, Steinberg M
Expert Rev Hematol
. 2024 Nov;
17(12):957-966.
PMID: 39535263
Introduction: Sickle cell disease is ameliorated and perhaps can be 'cured' if enough fetal hemoglobin is present in most erythrocytes. Hydroxyurea, which increases fetal hemoglobin levels, is widely available and...
3.
Sun Y, Benmhammed H, Al Abdullatif S, Habara A, Fu E, Brady J, et al.
Sci Adv
. 2024 Jul;
10(31):eadn8750.
PMID: 39083598
Sickle cell disease is a growing health burden afflicting millions around the world. Clinical observation and laboratory studies have shown that the severity of sickle cell disease is ameliorated in...
4.
Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, et al.
N Engl J Med
. 2024 Apr;
390(18):1649-1662.
PMID: 38661449
Background: Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of...
5.
Heitzer A, Rashkin S, Trpchevska A, Longoria J, Rampersaud E, Olufadi Y, et al.
Curr Res Transl Med
. 2024 Jan;
72(2):103433.
PMID: 38244277
Purpose: Neurocognitive impairment is a common and debilitating complication of sickle cell disease (SCD) resulting from a combination of biological and environmental factors. The catechol-O-methyltransferase (COMT) gene modulates levels of...
6.
Steinberg M, Gladwin M
Am J Hematol
. 2023 Jul;
98(10):1508-1511.
PMID: 37449407
No abstract available.
7.
Ribeil J, Pollock G, Frangoul H, Steinberg M
Am J Hematol
. 2023 May;
98(7):1087-1096.
PMID: 37170801
Hydroxyurea, the first approved drug for sickle cell disease, decreases sickle hemoglobin polymerization by inducing fetal hemoglobin. Its effects in young children are excellent; responses in adults are variable and...
8.
Sebastiani P, Steinberg M
Am J Hematol
. 2022 Nov;
98(2):E32-E34.
PMID: 36420999
No abstract available.
9.
Cyrus C, Vatte C, Al-Nafie A, Chathoth S, Akhtar M, Darwish M, et al.
Medicina (Kaunas)
. 2022 Oct;
58(10).
PMID: 36295630
: Sickle cell anemia (SCA) is a hereditary monogenic disease due to a single β-globin gene mutation that codes for the production of sickle hemoglobin. Its phenotype is modulated by...
10.
Minniti C, Brugnara C, Steinberg M
Am J Hematol
. 2022 Sep;
97(11):1390-1393.
PMID: 36073655
No abstract available.